BLUE — bluebird bio Income Statement
0.000.00%
Last trade - 00:00- $48.67m
- $129.31m
- $83.81m
- 23
- 48
- 51
- 36
Annual income statement for bluebird bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 3.66 | 3.6 | 29.5 | 83.8 |
| Cost of Revenue | |||||
| Gross Profit | 0 | -35.2 | -6.48 | -4.03 | -5.57 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 559 | 595 | 254 | 274 | 354 |
| Operating Profit | -559 | -591 | -250 | -244 | -270 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -560 | -562 | -230 | -212 | -241 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -561 | -563 | -230 | -212 | -241 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -619 | -819 | -230 | -212 | -241 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -619 | -819 | -230 | -212 | -241 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -180 | -158 | -74.7 | -49.6 | -24.7 |